FY2025 · ended Dec 31, 2025 · Revenue $767,000, +10857.1% YoY · Filed Mar 31, 2026
Guided Therapeutics, Inc. (GTHP) files with the SEC under industry code 3845, Electromedical & Electrotherapeutic Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $767,000 and a net loss of $3.2 million. Free cash flow was -$1.1 million. As of Jun 30, 2026 it held $12,000 in cash and investments and $736,000 in total debt.
Revenue (TTM)
$650,000
+450.8% vs year-ago TTM
Net income (TTM)
$-3.06M
-20.6% vs year-ago TTM
Operating cash flow (TTM)
$-1.50M
-15.2% vs year-ago TTM
Free cash flow
$-1.07M
+38.7% vs prior year
EPS (TTM)
$-0.04
-1.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
96.35M
+23.6% vs prior year
Net cash
$-724,000
as of Jun 30, 2026
Operating margin
-303.8%
FY 2026
Company profile
- Industry
- Electromedical & Electrotherapeutic Apparatus (SIC 3845)
- Listed as
- GTHP (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Peachtree Corners, GA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 924515
- Former names
- SPECTRX INC (until Feb 28, 2008)
Other Electromedical & Electrotherapeutic Apparatus companies
- Medtronic plc MDT
- LivaNova PLC LIVN
- Integer Holdings Corp ITGR
- Axogen, Inc. AXGN
- TransMedics Group, Inc. TMDX
- CONMED Corp CNMD
- Ceribell, Inc. CBLL
- InMode Ltd. INMD
All 31 Electromedical & Electrotherapeutic Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $767,000 | $7,000 | $98,000 | $13,000 | $81,000 |
| Operating income | -$2.4M | -$2.1M | -$3.5M | -$3.3M | -$2.4M |
| Net income | -$3.2M | -$2.4M | -$3.5M | -$4.3M | -$2.1M |
| Diluted EPS | -$0.04 | -$0.05 | -$0.07 | -$0.15 | -$0.18 |
| Operating cash flow | -$1.1M | -$1.1M | -$1.7M | -$1.5M | -$1.6M |
| Free cash flow | -$1.1M | — | -$1.7M | -$1.5M | -$1.6M |
| Total assets | $1.3M | $1.4M | $1.7M | $3.4M | $2.0M |
| Total liabilities | $7.3M | $6.3M | $5.5M | $6.2M | $7.5M |
| Stockholders' equity | -$6.0M | -$4.9M | -$3.8M | -$2.9M | -$5.4M |
| Cash and investments | $63,000 | $388,000 | $591,000 | $2.3M | $643,000 |
| Total debt | $696,000 | $155,000 | $246,000 | $342,000 | $1.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Mar 31, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Mar 10, 2026 | Mar 2, 2026 |
| 10-Q | Quarterly report | Nov 13, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
All 1000 Guided Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.